Foster Jonathan P. reported option exercise involving 41 derivative units of Moleculin Biotech, Inc. at $0.00 for $0 on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 6, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
41Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
70,854Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 6, 2026, 5:03 PM ET2-day reporting delay
Accession
0001437749-26-035617Code M · Transaction 395138
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Tax withholding10$8.46−$84.60Trade 395137
Nov 4, 2026Option exercise41——Trade 395136
3 transaction rows in this filing. Joint filers share the same rows.

MBRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MBRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago +0.6%1d ago −4.5%
Returns since7d −9.4%30d90d180d1y

Footnotes in full

F1: Restricted stock units convert into common stock on a one-for-one basis. F2: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. F3: On November 4, 2024, the reporting person was granted 165 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.